Combined Modality Therapy ; Humans ; Non-alcoholic Fatty Liver Disease

Humans ; Non-alcoholic Fatty Liver Disease ; diagnosis ; therapy

Fatty Liver ; therapy ; Humans ; Integrative Medicine ; Non-alcoholic Fatty Liver Disease

Fatty Liver ; diagnosis ; therapy ; Humans ; Non-alcoholic Fatty Liver Disease ; Practice Guidelines as Topic ; United States

Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and a common cause of liver cirrhosis and cancer. Akkermansia muciniphila (A. muciniphila) is a next-generation probiotic that has been reported to improve metabolic disorders. Emerging evidence indicates the therapeutic potential of A. muciniphila for NAFLD, especially in the inflammatory stage, nonalcoholic steatohepatitis. Here, the current knowledge on the role of A. muciniphila in the progression of NAFLD was summarized. A. muciniphila abundancy is decreased in animals and humans with NAFLD. The recovery of A. muciniphila presented benefits in preventing hepatic fat accumulation and inflammation in NAFLD. The details of how microbes regulate hepatic immunity and lipid accumulation in NAFLD were further discussed. The modulation mechanisms by which A. muciniphila acts to improve hepatic inflammation are mainly attributed to the alleviation of inflammatory cytokines and LPS signals and the downregulation of microbiota-related innate immune cells (such as macrophages). This review provides insights into the roles of A. muciniphila in NAFLD, thereby providing a blueprint to facilitate clinical therapeutic applications.
Humans ; Animals ; Non-alcoholic Fatty Liver Disease/therapy* ; Liver Cirrhosis ; Inflammation

Genetic Predisposition to Disease ; Humans ; Non-alcoholic Fatty Liver Disease ; diagnosis ; genetics ; therapy

Fatty Liver ; complications ; epidemiology ; therapy ; Female ; Humans ; Insulin Resistance ; Non-alcoholic Fatty Liver Disease ; Polycystic Ovary Syndrome ; complications ; epidemiology ; therapy

Acupuncture Points ; Adult ; Electroacupuncture ; Fatty Liver ; therapy ; Female ; Humans ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease

OBJECTIVETo evaluate the efficacy of antioxidants in the treatment of non-alcoholic fatty liver.

METHODSThe Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE or PUBMED (1978-2011), EMBASE (1978-2011), ISI, OVID Database (1978-2011), CNKI Net and WANFANG database (1978-2011) were searched for relevant randomized controlled trials, with also manual search of the bibliographies of the retrieved articles. The data were synthesized to assess the histological response of the patients (hepatic steatosis, inflammation and fibrosis) and hepatic biochemical changes after the treatments (alanine aminotransferase responses).

RESULTSFourteen trials involving 1284 patients were included in the Meta-analysis. The quality of the trials was inconsistent. The data were extracted for meta-analysis or descriptive analysis, which did not yield sufficient evidence that antioxidants could improve hepatic steatosis, inflammation, fibrosis or alanine aminotransferase responses.

CONCLUSIONSThe current data do not support a positive therapeutic effect of antioxidants on nonalcoholic fatty liver, and antioxidants are therefore not recommended in the clinical treatment of the condition.

Adult ; Fatty Liver ; diagnosis ; drug therapy ; Female ; Humans ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Waist-Hip Ratio